Sartorius Stedim Biotech
Universal Registration Document
Including the Annual Financial Report
2022
“After two exceptionally dynamic years, we delivered another year of strong results. Despite the challenging operating environment, our growth was broad-based across the portfolio and the geographies, and we see us a good year ahead of our mid-term plan. Not surprisingly, 2023 will show a trend back towards our underlying growth path.
As we look ahead, we find the fundamental growth drivers in our markets fully intact. Demand for biopharmaceuticals is on the rise in all indication areas and regions, and at the same time the biotech industry is in an extraordinarily innovative phase. We are excellently positioned to support our customers in their endeavors and to seize the opportunities that arise from this. Substantial investments into capacities and acquisitions that expand our capabilities will therefore remain part of our growth strategy.”
Sales revenue
€3,492.7m
in constant FX: +15.1%
Underlying EBITDA
€1,221.4m
+18.2%
Order intake
€3,314.8m
in constant FX: -13.0%
Employees
11,934
+1,525
Market capitalization
~€27.9bn
-37.7%
Group Business Development
Following extraordinary growth in 2020 and 2021, Sartorius Stedim Biotech, a leading partner of the biopharma industry, again outperformed the market in fiscal 2022. According to preliminary figures, the company recorded double-digit percentage growth in sales revenue and earnings year-over-year.
Outlook
Following the exceptionally strong previous years, Sartorius Stedim Biotech expects further growth in 2023 despite demand normalization and anticipated further declines in the Covid-19-related business. In addition, management adjusted the medium-term sales revenue forecast in light of increased inflation and associated price adjustments.